Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 305 • 2019 ACR/ARP Annual Meeting
Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing
Caleb Anderson¹, Roger Stitt ² and Robert O'Brian ¹, ¹Walter Reed National Military Medical Center, Bethesda, MD, ²US Army, Ft Eustis
Background/Purpose: Greater emphasis has been placed on cost saving measures due to ballooning healthcare cost in the U.S. ACGME now evaluates trainee ability to practice…
Abstract Number: 20 • 2019 ACR/ARP Annual Meeting
Comparative Efficacy of Beta-2-Glycoprotein I Domain V Structural Analogue Variants in Preventing Antiphospholipid Antibody-Mediated Endothelial Cell Activation
Rohan Willis¹, Elizabeth Papalardo ¹, Mohammad Jamaluddin ¹, Zurina Romay-Penabad ¹, Alvaro Schleh ¹, Allan Brasier ¹ and Emilio B Gonzalez ², ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, Galveston
Background/Purpose: In previous studies, our group has demonstrated that a synthetic 20 amino acid peptide (“TIFI”) with structural similarity to Beta-2-Glycoprotein I Domain V (β2GPI…
Abstract Number: 1788 • 2019 ACR/ARP Annual Meeting
Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome
Yu Zuo¹, Srilakshmi Yalavarthi ², Kelsey Gockman ², David Karp ³, Quan-Zhen Li ⁴ and Jason Knight ⁵, ¹University of Texas Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³UTSouthwestern Medical Center, Dallas, TX, ⁴Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic tangles of chromatin and microbicidal proteins ejected from neutrophils in response to a variety of stimuli. In antiphospholipid…
Abstract Number: 73 • 2019 ACR/ARP Annual Meeting
Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome
Ramadan Ali¹, Julia Weiner ¹, Alex Gandhi ¹, Shanea Estes ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: 6-gingerol, the major bioactive compound of ginger root, is known to have anti-inflammatory and anti-oxidative effects. Indeed, ginger has been employed for millennia as…
Abstract Number: 1792 • 2019 ACR/ARP Annual Meeting
Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)
Renata Rosa¹, Michelle Remião Ugolini-Lopes ², Ana Paula Gandara ², Kenia Campanholo ², Livia Dutra ³ and Danieli Andrade ⁴, ¹Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Brazil, ³Escola Paulista de Medicina (EPM), Brazil, São Paulo, Brazil, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Cognition dysfunction (CD) is a poorly understood non-stroke central neurologic manifestation of antiphospholipid syndrome, whose diagnosis involves a specific neuropsychological (NP) evaluation. Brain-derived neurotrophic…
Abstract Number: 88 • 2019 ACR/ARP Annual Meeting
Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets
Irene Cecchi¹, Massimo Radin ¹, Elena Rubini ¹, Silvia Grazietta Foddai ¹, Ana Suarez ², Elisa Menegatti ¹, Dario Roccatello ¹, Savino Sciascia ³ and Javier Rodriguez Carrio ², ¹University of Turin, Turin, Italy, ²University of Oviedo, Oviedo, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: Type I Interferons (IFN) play a key role in the pathogenesis and evolution of various autoimmune diseases. Previous studies have demonstrated that the expression…
Abstract Number: 1793 • 2019 ACR/ARP Annual Meeting
Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Maxime Taghavi¹, Medha Barbhaiya ², Maria Tektonidou ³, Paul Fortin ⁴, Danieli Andrade ⁵, Jason Knight ⁶, Bahar Artim-Esen ⁷, Tatsuya Atsumi ⁸, Hannah Cohen ⁹, Lanlan Ji ¹⁰, Savino Sciascia ¹¹, Surya Seshan ¹², Doruk Erkan ¹³ and on Behalf of APS ACTION ¹⁴, ¹Brugmann Hospital, Brugmann, Belgium, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ⁵Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁶Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁷Istanbul University School of Medicine, Istanbul, Turkey, ⁸Hokkaido University, Sapporo, Japan, ⁹University College London, London, United Kingdom, ¹⁰Peking University First Hospital, Beijing, China (People's Republic), ¹¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ¹²Weill Cornell Medicine, New York, ¹³Hospital for Special Surgery, New York City, ¹⁴Hospital for Special Surgery, New York
Background/Purpose: Antiphospholipid antibody (aPL) nephropathy is a distinct entity that can be challenging to recognize and treat; it remains unknown if uniform pathologic criteria are…
Abstract Number: 157 • 2018 ACR/ARHP Annual Meeting
Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients
Yu Zuo¹, Chun Li², Song Zhang³, Una Makris¹, David Karp⁴ and Zhan-Guo Li⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Peking University People's Hospital, Beijing, China, ³University of Texas Southwestern Medical Center, dallas, TX, ⁴Rheumatology, UT Southwestern Med Ctr, Dallas, TX, ⁵Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Risk stratification of asymptomatic aPL carriers is difficult. Our objective was to identify additional clinical and epidemiological predictors of arterial thrombosis, venous thrombosis, and…
Abstract Number: 158 • 2018 ACR/ARHP Annual Meeting
Incidence and Prevalence of Antiphospholipid Syndrome in a Health Management Organization (HMO): A 15-Year Study
Aurelia Luissi¹, Marina Scolnik² and Enrique R Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: Antiphospholipid Syndrome (APS) is an unusual disease and there are scarce epidemiological data. Our objective was to assess incidence and prevalence rates of APS…
Abstract Number: 162 • 2018 ACR/ARHP Annual Meeting
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa
Ecem Sevim¹, Salma Siddique², Susan Chyou³, William D. Shipman³, Ines Eugenio-Fernandez⁴, Ariel Badger⁴, Orla O`Shea⁵, Stephane Zuily⁶, Joanna Harp⁷, Cynthia Magro⁸, Oral Alpan⁹, Theresa T. Lu¹⁰ and Doruk Erkan¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Pediatric Rheumatology, Nemours Children's Health System, Wilmington, DE, ³Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ⁴O&O Alpan Medical Center, Fairfax, VA, ⁵Analytical Microscopy Core Laboratory, Hospital for Special Surgery, New York, NY, ⁶Université de Lorraine, CHRU Nancy, Nancy, France, ⁷Dermatology, Weill Cornell Medicine, New York, NY, ⁸Pathology, Weill Cornell Medicine, New York, NY, ⁹Allergy & Immunology, O&O Alpan Medical Center, Fairfax, VA, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: Endothelial proliferation is a key finding in antiphospholipid antibody (aPL)-positive patients with microthrombosis. The mTOR pathway plays a role in the endothelial proliferation leading…
Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
Abstract Number: 171 • 2018 ACR/ARHP Annual Meeting
Flow Cytometric Assessment of the Mammalian Target of Rapamycin Pathway Using Antiphospholipid Syndrome As a Disease Model
Ariel Badger¹, Ecem Sevim², Oral Alpan³ and Doruk Erkan⁴, ¹O&O Alpan Medical Center, Fairfax, VA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Allergy & Immunology, O&O Alpan Medical Center, Fairfax, VA, ⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: The mammalian target of rapamycin (mTOR) is a component of MTOR complex-1 that, when activated by upstream molecule protein kinase B (AKT) and another…
Abstract Number: 172 • 2018 ACR/ARHP Annual Meeting
Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study
Laura-Aline Martinez-Martinez¹, Fausto Sanchez-Muñoz², Maya Jazmin Nastia Nicte Chacon-Perez², Yaneli Juarez-Vicuña², Nicole Mouneu Ornelas¹, Anthony Beltran-Cortez², Ricardo Alberto Venegas Yañez³, Julio Fonseca Basurto¹, Evelyn Aranda Cano¹, Mary Carmen Amigo⁴ and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Reumatologia, Instituto Nacional de Cardiología "Ignacio Chavez", Ciudad de México, Mexico, ⁴Rheumatology, Centro Medico ABC, Mexico, Mexico
Background/Purpose: Recent evidence suggests that chemokines and miRNAs are involved in the pathogenesis of antiphospholipid syndrome (APS). However, the specific role of these molecules in…
Abstract Number: 174 • 2018 ACR/ARHP Annual Meeting
Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial
Josefina Cortés-Hernández¹, Luis Sáez-Comet², Antoni Riera Mestre³, A. Castro Salomó⁴, J. Cuquet Pedragosa⁵, Vera Ortiz-Santamaría⁶, M. Mauri Plana⁷ and Josep Ordi-Ros⁸, ¹Internal Medicine Department, Vall d´Hebron Hospital, Barcelona, Spain, ²Internal Medicine, Miguel Servet University Hospital, Zaragoza, Spain, ³VTE Unit. Internal Medicine, Bellvitge University Hospital, Barcelona, Spain, ⁴Hospital Universitari de Reus, Spain, Reus, Spain, ⁵Internal Medicine, Granollers University Hospital, Granollers, Spain, ⁶Rheumatology, Hospital General. Granollers., Granollers, Spain, ⁷Internal Medicine, Mataró Hospital, Mataró, Spain, ⁸Internal Medicine, Vall d'Hebron Hospital, Barcelona, Spain
Background/Purpose: Long-term anticoagulation with vitamin K antagonists (VKAs) is the standard of care in thrombotic antiphospholipid syndrome (APS) but requires frequent monitoring and dose adjustment.…
Abstract Number: 851 • 2018 ACR/ARHP Annual Meeting
Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Andrew Vreede², Omolola Eniola-Adefeso¹ and Jason S. Knight³, ¹University of Michigan, Ann Arbor, MI, ²Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³., University of Michigan, Ann Arbor, MI
Background/Purpose: While the role of antiphospholipid antibodies in activating endothelial cells has been extensively studied, the impact of these antibodies on the adhesive potential of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].